Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn about a recent article by Azmi Eyiol, published in Journal of Clinical Medicine, adding:
“A new multicenter study in acute coronary syndrome puts two simple blood-based scores under the microscope: PIV, a combined immune-inflammation value, and HALP, a score built from hemoglobin, albumin, lymphocytes and platelets.
In 1.134 hospitalized patients, HALP predicted mortality better than PIV, with an AUROC of 0.722 versus 0.619, meaning it separated higher-risk from lower-risk patients more reliably.
The striking part is that this signal came from routine admission labs, not from a complex new test.”
Title: Pan-Immune-Inflammatory Value (PIV) and HALP Score as Independent Prognostic Indicators in Acute Coronary Syndrome Patients
Authors: Azmi Eyiol, Hatice Eyiol, Ahmet Yilmaz, Hasan Sari
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge
-
Sep 29, 2026, 16:18Edward Lee Carter: Why Periprocedural DOAC Guidance Needs a Common Output Standard
-
Sep 29, 2026, 16:07Yasmine Laraba: Deep Vein Thrombosis Causes, Signs and Management